Filing Details

Accession Number:
0001140361-12-024087
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2012-05-09 18:38:02
Reporting Period:
2012-04-02
Filing Date:
2012-05-09
Accepted Time:
2012-05-09 18:38:02
Original Submission Date:
2012-04-04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070698 Raptor Pharmaceutical Corp RPTP Pharmaceutical Preparations (2834) 860883978
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1362489 Raymond Anderson C/O Raptor Pharmaceutical Corp.
9 Commercial Blvd., Suite 200
Novato CA 94949
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-04-02 6,128 $2.57 6,128 No 4 M Direct
Common Stock Disposition 2012-04-02 6,128 $6.72 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock options (right to buy) Disposition 2012-04-02 6,128 $0.00 6,128 $2.57
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
382,619 2006-11-26 2016-05-25 No 4 M Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2012.
  2. Original option grant vests 6/36ths on November 26, 2006 and 1/36th per month thereafter.
  3. This Form 4/A corrects the Amount of Securities Beneficially Owned (reference the original Form 4 - Table I Item 5).
  4. This transaction was executed in multiple trades at prices ranging from $6.70 to $6.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. This Form 4/A corrects the Number of Derivative Securities Beneficially Owned (reference the original Form 4 - Table II Item 9).